Purpose

This is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of sotatercept versus placebo in adults with Cpc-PH due to HFpEF. The objective of this study is to evaluate the efficacy, safety and tolerability of sotatercept versus placebo in adults with Cpc-PH due to HFpEF. Efficacy is measured by change from baseline in pulmonary vascular resistance (PVR, primary endpoint) and 6-minute walk distance (6MWD, key secondary endpoint).

Condition

Eligibility

Eligible Ages
Between 18 Years and 85 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

Participants must meet the following criteria to be enrolled in this proof-of-concept study: 1. Age 18 to 85 years 2. Clinical diagnosis of HFpEF: • Left ventricular ejection fraction ≥ 50%, with no history of LVEF below 45% 3. Demonstrated Cpc-PH by all of the following: - Baseline RHC performed within 10 days prior to Visit 1 (during the Screening Period) documenting a minimum PVR of ≥ 320 dyn•sec/cm5 (4 wood units) - Mean pulmonary arterial pressure (mPAP) of > 20 mmHg - Pulmonary capillary wedge pressure (PCWP) > 15 mmHg but < 30 mmHg 4. New York Heart Association FC of II or III 5. Six-Minute Walk Distance ≥ 100 m repeated twice during Screening and both values within 15% of each other, calculated from the highest value 6. Chronic medication for HF or for any underlying condition, administered at a stable (per investigator) dose for ≥ 30 days prior to Visit 1. Diuretics and/or anticoagulants are excepted from this rule but should not be newly started or stopped within 30 days of Visit 1, and a prescribed dose change should not occur within 7 days of Visit 1. Anticoagulation may be suspended for RHC if necessary. 7. Women of childbearing potential must: - Have a negative pregnancy test as verified by the investigator prior to starting study drug administration; she must agree to ongoing pregnancy testing during the course of the study and until 8 weeks after the last dose of the study drug - If sexually active, have used and agree to continue to use highly effective contraception without interruption for at least 28 days prior to starting the investigational product, during the study (including dose interruptions), and for 16 weeks (112 days) after discontinuation of study drug - Refrain from breastfeeding a child or donating blood, eggs, or ovum for the duration of the study and for at least 16 weeks (112 days) after the last dose of study drug See Appendix 2 for additional contraceptive information. 8. Male participants must: - Agree to use a condom, defined as a male latex condom or non latex condom NOT made out of natural (animal) membrane (e.g., polyurethane), during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions, and for at least 16 weeks (112 days) following investigational product discontinuation, even if he has undergone a successful vasectomy - Refrain from donating blood or sperm for the duration of the study and for 16 weeks (112 days) after the last dose of study drug 9. Ability to adhere to the study visit schedule and understand and comply with all protocol requirements 10. Agreement to not participate in any other trials of investigational drugs/devices while enrolled in the A011-16 study 11. Ability to understand and provide written informed consent for participation

Exclusion Criteria

Participants will be excluded from the study if any of the following criteria are met: 1. A diagnosis of PH in WHO Group 1, WHO Group 3, WHO Group 4, or WHO Group 5 2. Significant parenchymal lung disease (e.g., chronic obstructive pulmonary disease with Global Initiative for Obstructive Lung Disease (GOLD) criteria III and IV, moderate or severe restrictive lung disease, diffuse interstitial fibrosis or alveolitis, pulmonary thromboembolism) 3. Cardiovascular co-morbidities, which include any of the following: - Any history of greater than mild mitral regurgitation or aortic regurgitation valvular disease or greater than mild aortic or mitral stenosis - Acute coronary syndrome, coronary artery bypass graft or percutaneous coronary intervention within 180 days of Visit 1 - Uncontrolled heart rate (> 100 bpm) from atrial fibrillation or atrial flutter - History of serious life-threatening or hemodynamically significant arrhythmia - History of or anticipated heart transplant or ventricular assist device implantation - History of or anticipated implantation of pacemaker or implantable cardioverter defibrillator - Occurrence of myocardial infarction within 90 days of Visit 1 - History of known pericardial constriction, hypertrophic cardiomyopathy, sarcoidosis, or amyloid cardiomyopathy - Uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure > 160 mmHg or sitting diastolic blood pressure > 110 mmHg during Screening after a period of rest - Systemic hypotension as evidenced by sitting systolic blood pressure < 90 mmHg or sitting diastolic blood pressure < 50 mmHg during Screening - Resting heart rate of < 45 bpm or > 115 bpm - Cerebrovascular accident within 90 days of Visit 1 - Acutely decompensated HF within 45 days prior to Visit 1, as per investigator assessment - Electrocardiogram (ECG) during Screening Period with Fridericia's corrected QT interval (QTcF) > 480 msec or > 500 msec if a ventricular conduction defect (right bundle branch block; left bundle branch block; or interventricular conduction delay) is present - Personal or family history of long corrected QT syndrome or sudden cardiac death in first-degree relative 4. Hospitalization for any indication within 30 days of Visit 1 5. Received any approved PAH-specific therapies (i.e., endothelin receptor antagonists, prostacyclin analogs, phosphodiesterase-5 inhibitors, or soluble guanylate cyclase stimulators) within 30 days prior to Visit 1 6. Received intravenous inotropes (e.g., dobutamine, dopamine, norepinephrine, vasopressin) within 30 days prior to Visit 1 7. Received erythropoietin within 6 months prior to Visit 1 8. Known history of chronic liver disease, including untreated hepatitis B and/or hepatitis C (with evidence of recent infection and/or active virus replication), defined as mild to severe hepatic impairment (Child-Pugh Class A through C) 9. Prior exposure to sotatercept or luspatercept 10. Currently enrolled in or have completed any other investigational product study within 30 days for small molecule drugs or within 5 half-lives for biologics prior to the date of signed informed consent 11. Initiation of an exercise program for cardiopulmonary rehabilitation within 90 days prior to Visit 1 or planned initiation during the study (participants who are stable in the maintenance phase of a program and who will continue for the duration of the study are eligible) 12. Any of the following clinical laboratory values prior to Visit 1 as specified: - Hemoglobin (Hgb) above the gender-specific upper limit of normal (ULN) per local laboratory test within 28 days of Visit 1or < 10 g/dL per local laboratory within 28 days of Visit 1 - Serum alanine aminotransferase or aspartate aminotransferase levels > 3× ULN or total bilirubin > 1.5× ULN within 28 days of Visit 1 - Estimated glomerular filtration rate < 30 ml/min/1.73 m2 (4-variable Modification of Diet in Renal Disease equation) within 28 days of Visit 1 or required renal replacement therapy within 90 days of Visit 1 - Glycated hemoglobin (HbA1c) > 10% within 28 days of Visit 1 - Platelet count < 75,000/mm3 within 28 days of Visit 1 13. History of severe allergic or anaphylactic reaction or hypersensitivity to recombinant proteins or excipients in the investigational product 14. Major surgery within 60 days prior to Visit 1. Participants must have completely recovered from any previous surgery prior to Visit 1 15. Prior heart-lung transplants or life expectancy of < 12 months 16. Pregnancy or breastfeeding in females 17. History of active malignancy, with the exception of fully excised or treated basal cell carcinoma, cervical carcinoma in situ, or ≤ 2 squamous cell carcinomas of the skin 18. History of clinically significant (as determined by the investigator) endocrine, hematologic, hepatic, (auto)immune, metabolic, urologic, pulmonary, neurologic, neuromuscular, dermatologic, psychiatric, renal, and/or another disease that may limit participation in the study 19. Body mass index ≥ 45 kg/m2

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Intervention Model Description
Each eligible participant will be randomly assigned in a 1:1:1 ratio to 1 of the 3 treatment groups during the Treatment Period: Arm 1: Treatment Group 1: Placebo delivered subcutaneously (SC) every 3 weeks (Q3W) for 24 weeks Arm 2: Treatment Group 2: Sotatercept SC at a dose level of 0.3 mg/kg Q3W for 24 weeks Arm 3: Treatment Group 3: Sotatercept SC at a starting dose level of 0.3 mg/kg for 3 dosing visits (Q3W), then escalating to 0.7 mg/kg SC on the fourth dosing visit and Q3W for the remainder of the 24-week Treatment Period
Primary Purpose
Treatment
Masking
Triple (Participant, Care Provider, Investigator)

Arm Groups

ArmDescriptionAssigned Intervention
Placebo Comparator
Placebo
Delivered subcutaneously (SC) every 3 weeks (Q3W) for 24 weeks.
  • Drug: Placebo
    Placebo
Experimental
Sotatercept 0.3 mg/kg
Sotatercept SC at a dose level of 0.3 mg/kg Q3W for 24 weeks.
  • Drug: Sotatercept
    Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
    Other names:
    • ACE-011
Experimental
Sotatercept 0.3 mg/kg, escalating to 0.7 mg.kg
Sotatercept SC at a starting dose level of 0.3 mg/kg for 3 dosing visits (Q3W), then escalating to 0.7 mg/kg SC on the fourth dosing visit and Q3W for the remainder of the 24-week Treatment Period.
  • Drug: Sotatercept
    Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
    Other names:
    • ACE-011

Recruiting Locations

University of Kansas Medical Center ( Site 1020)
Kansas City, Kansas 66160
Contact:
Study Coordinator
913-588-2314

More Details

Status
Recruiting
Sponsor
Acceleron Pharma Inc.

Study Contact

Toll Free Number
1-888-577-8839
Trialsites@merck.com

Detailed Description

Participants enrolled in the study will have a diagnosis of Cpc-PH due to HFpEF with New York Heart Association (NYHA) functional class (FC) II or III. Participants will be randomly assigned in a 1:1:1 ratio to 1 of the 3 treatment groups (placebo, 0.3mg/kg sotatercept and 0.7mg/kg sotatercept) during the placebo-controlled Treatment Period. In the extension phase, sotatercept-treated participants will continue on their current dose. Placebo participants will be re-randomized in a 1:1 ratio to one of the two sotatercept treatment groups utilized in the placebo-controlled Treatment Period. Each participant will be enrolled in the study for up to 114 weeks, including a 28-day Screening Period, a 24-week, double-blind, placebo-controlled Treatment Period, an 18-month Extension Period, and an 8-week Follow-up Period.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.